TRCT
NUVB icon

Tower Research Capital (TRC)’s Nuvation Bio NUVB Stock Holding History

Tower Research Capital (TRC)’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$85K Buy
19,809
+2,757
+16% +$15.4K ﹤0.01% 2318
2025
Q4 		$153K Buy
17,052
+9,569
+128% +$59.3K ﹤0.01% 1643
2025
Q3 		$27.7K Sell
7,483
-19,975
-73% -$54.4K ﹤0.01% 3019
2025
Q2 		$53.5K Buy
27,458
+20,244
+281% +$42.2K ﹤0.01% 2918
2025
Q1 		$12.7K Buy
7,214
+2,908
+68% +$6.62K ﹤0.01% 3428
2024
Q4 		$11.5K Sell
4,306
-3,992
-48% -$10.3K ﹤0.01% 3713
2024
Q3 		$19K Sell
8,298
-11,575
-58% -$35.3K ﹤0.01% 3265
2024
Q2 		$58K Buy
19,873
+3,159
+19% +$9.64K ﹤0.01% 2983
2024
Q1 		$60.8K Buy
16,714
+8,139
+95% +$15.6K ﹤0.01% 2144
2023
Q4 		$12.9K Sell
8,575
-3,641
-30% -$4.69K ﹤0.01% 3998
2023
Q3 		$16.4K Buy
12,216
+8,856
+264% +$14.7K ﹤0.01% 3562
2023
Q2 		$6.05K Sell
3,360
-30,910
-90% -$52.5K ﹤0.01% 4746
2023
Q1 		$57K Buy
34,270
+24,315
+244% +$49.3K ﹤0.01% 2378
2022
Q4 		$19K Buy
9,955
+1,199
+14% +$2.43K ﹤0.01% 3180
2022
Q3 		$20K Sell
8,756
-646
-7% -$1.84K ﹤0.01% 3938
2022
Q2 		$30K Buy
9,402
+8,164
+659% +$35.6K ﹤0.01% 3382
2022
Q1 		$7K Sell
1,238
-1,350
-52% -$7.58K ﹤0.01% 4742
2021
Q4 		$22K Sell
2,588
-1,110
-30% -$10.2K ﹤0.01% 3564
2021
Q3 		$37K Buy
3,698
+2,913
+371% +$26.4K ﹤0.01% 3200
2021
Q2 		$7K Buy
785
+110
+16% +$1.25K ﹤0.01% 4561
2021
Q1 		$7K Sell
675
-641
-49% -$7.17K ﹤0.01% 4542
2020
Q4 		$15K Buy
+1,316
New +$13.7K ﹤0.01% 4050

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Tower Research Capital (TRC)'s NUVB Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Nuvation Bio (NUVB) stake by 16% in Q1 2026, buying an estimated $15.4K and bringing the position to 19,809 shares worth $85K. The position accounts for ﹤0.01% of the portfolio, ranked #2318.

Tower Research Capital (TRC) first reported a position in NUVB in Q4 2020 and has held it in 22 quarters since. The position peaked at $153K in Q4 2025. 231 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

  • Tower Research Capital (TRC) held 19,809 shares of Nuvation Bio worth $85K as of Q1 2026.
  • Tower Research Capital (TRC) bought 2,757 Nuvation Bio shares in Q1 2026, an estimated $15.4K.
  • Nuvation Bio made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2318 holding.
  • Tower Research Capital (TRC) first reported a position in Nuvation Bio in Q4 2020 and has held it in 22 quarters since.
  • Tower Research Capital (TRC)'s Nuvation Bio position peaked at $153K in Q4 2025.
  • 231 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.